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Summary The 1q13 chromosomal region encodes oncogenes relevant to a variety of human cancers as well
as a tumour suppressor gene implicated in multiple endocrine neoplasia type 1. In addition, high affinity folate
receptor (FOLRI), which maps to Iq13.3- 13.5, is expressed at an elevated level on the surface of over 80%
of nonmucinous epithelial ovarian cancers. Further telomeric, 1 lq breakpoints are found in many cancers. We
studied the involvement of 1 lq markers in ovarian cancer by looking for tumour-specific loss ofheterozygosity
(LOH), as well as amplification or rearrangements that might explain the overexpression of FOLR1. Twenty
eight epithelial ovarian cancers, along with lymphocyte DNA from the same individual were used for Southern
blotting with polymorphic probes from lq. PCR primers from lq23.3 were also used. The 1q13 band was
amplified in four out of 28 cancers. The amplicon included the probe D11S146 as well as FGF3 (formerly
INT2) and FOLRI in one out of these four cases, thus crossing the bcll translocation breakpoint. LOH was
seen in three out of 16 cases with FGF3 (1 1q13). A much higher frequency of LOH (8/12) was found at
llq23.3-qter, implying the presence of a tumour suppressor gene in this region.
Over the last few years, understanding of the molecular
pathology of ovarian cancer has been advanced both by
looking for loss of heterozygosity (LOH) that may be re-
vealed by utilising restriction fragment length polymorphisms
(RFLPs), recognised by DNA probes, and by studies of
amplification and/or rearrangement of candidate oncogenes.
We have used these techniques to study both LOH and
amplification on the long arm ofchromosome 11 in epithelial
ovarian cancer (EOC).
Molecular abnormalities of chromosome 11 have been
reported in EOC, but most studies have concentrated on
LOH involving known genes such as HRAS and insulin,
both mapping to lplS.5 (Lee et al., 1989; Ehlen & Dubeau,
1990; Lee et al., 1990; Sato et al., 1991; Viel et al., 1991). In
contrast, chromosome lq has not received much attention
in EOC. Three LOH studies (Lee et al., 1990; Li et al., 1991;
Sato et al., 1991) in EOC have used a probe derived from
FGF3, (previously INT2), which maps to Iq13.3- 13.5 (Rag-
oussis et al., 1992), and is amplified in a limited number of
mainly epithelial tumours (Lammie & Peters, 1991). None of
the reports have noted amplification, and LOH appears to be
a very infrequent event. Sasano et al. (1990), reported
amplification of FGF3 in 1/16 carcinomas from a series of 24
ovarian tumours. They did not study LOH. Recently, Pejovic
et al. (1992) reported five cases of a translocation involving
1lq13 and other chromosomes in their series of 35 EOC
patients.
The multiple endocrine neoplasia type 1 (MENI) gene
maps to 1 1q13 (Larsson et al., 1988; Fujimori et al., 1992)
and LOH on 1 lq has been reported in MENl-associated
tumours (Friedman et al., 1989; Thakker et al., 1989). In
most cases, all informative probes on 1 lq showed LOH, but
given the linkage data, the tumour suppressor gene is likely
to be in 1Iq13. Significant LOH on llq has also been
reported in cervical cancer (Srivatsan et al., 1991a) and
neuroblastoma (Srivatsan et al., 1991b).
Campbell et al. (1991) and Coney et al. (1991) have
reported the cloning of the gene that encodes the antigen
recognised by MOvI8, a murine monoclonal antibody reac-
tive with over 80% of nonmucinous ovarian adenocar-
cinomas (Miotti et al., 1987). This gene is the adult high-
affinity folate receptor (FOLRJ) (Ratnam et al., 1989; El-
wood, 1989), which maps to llq13.3-13.5 (Ragoussis et al.,
1992). We noted its proximity to FGF3, to the bcll transloca-
tion breakpoint in B cell lymphomas, (Tsujimoto et al., 1985)
and to PRAD1, a bcll-linked gene which may be important
in 1q13 amplification (Rosenberg et al., 1991).
Given this background, we set out to determine what
contribution genetic alterations of chromosome lq might
have to ovarian carcinogenesis. In addition to data pertaining
to q13, there have been numerous cytogenetic reports in
EOC which include translocations and deletions involving
regions telomeric to 1q13 in EOC. Despite this, there have
been no molecular studies of these areas. We noted the
successful use of dinucleotide repeat primers in the study of
LOH in breast cancer by Futreal et al. (1992), where they
used primers mapping to chromosome 17. Therefore, as well
as RFLP DNA probes telomeric to 1 1q13, we used the
primers L7.1/2 and Mfd69, both of which map to Iq23.3.
By using these probes from 1 1q14- 1 lqter, we have extended
these findings with LOH data and defined the minimum
deleted region.
Materials and methods
Materials
Tumours were collected from consenting patients undergoing
surgery for ovarian cancer. Lymphocytes were extracted from
blood taken at the time or within a few days of the oper-
ation. These patients were unselected and were operated on
at a number of hospitals in and around London. Tumour
tissue was initially dissected, and then frozen in isopentane
before storing the samples in liquid nitrogen. Frozen sections
were then taken from representative parts of the tumour and
stained with haematoxylin and eosin. The proportion of
tumour to stroma was recorded. The frozen sections allowed
us to select the most tumour-rich part of the specimen for
further analysis. Classification of the ovarian tumours by
histopathological grade was carried out according to the
WHO classification (Serov et al., 1973, pp. 17-54), with
some modifications (Russell, 1987, pp. 556-622; Anderson,
1991, pp. 303-344). This method of classification is repro-
ducible; the criteria include architectural and cytological
features as well as the maximum mitotic index, nuclear mor-
phology and the degree of necrosis.
DNA extraction
DNA was extracted from the tumours using a modified
version of the protocol of Goelz et al. (1985). Instead of
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using phenol-chloroform in the final stages, we used salt-
chloroform, according to the method of Miillenbach et al.
(1989). Lymphocyte DNA was also extracted using the salt-
chloroform method.
DNA probes and dinucleotide repeat primers
The RFLP probes used in this study were pHO6Tl, HRAS
(Ilpl5.5); pBl-21A-29, CD20 (1lql2); pHB159, DJJS146
(llql2-13.2); SS6, FGF3 (1lqI3.3-5); cHTMOvI8, FOLRI
(1lqI3.3-5); pMEL34, TYR (lql4-21); STMY, STMYI
(1lq22); pMCT128.1, DIIS144 (1lq22.3-23.3); pHBI18P2,
D11S147 (1q23.3-qter). The two dinucleotide repeats used
for generation of LOH data via polymerase chain reaction
(PCR) were Mfd69, at CD3D and L7.1/2, at DIIS29. Both
of these repeats map to 1lq23.3
Southern transfer, hybridisation and autoradiography
DNA was digested with restriction endonucleases and size
fractionated through agarose gels. Southern transfer was car-
ried out using a vacuum blotter (Hybaid, Middlesex, UK)
onto Hybond N+ (Amersham International) and hybridisa-
tion was performed according to the manufacturers' instruc-
tions. DNA probes were labelled with a-[32P] dCTP using the
Feinberg and Vogelstein (1987) random priming protocol
and used at 1 x 106 c.p.m. per ml of hybridisation solution.
The filters were washed to 0.1 x SSC, 0.1% SDS at 65°C and
exposed to Kodak XAR-5 film at - 70°C. Assessment of
LOH and/or amplification of the tumours was based on
comparison with the adjacent 'normal' lane, previous hybri-
disation of the same filter where the loading was not equal,
and densitometry using an LKB Ultrascan XL Laser Densi-
tometer if there was any doubt.
Dinucleotide repeat analysis
PCRs were performed as described in the relevant publica-
tions (Weber et al., 1990; Warnich et al., 1992), except that
approximately 1 1.g of DNA was used in each 50iLl reaction,
and 35 cycles were carried out. Ten itl of the reaction prod-
uct, with tracking dye was then run on a 10% nondenaturing
polyacrylamide wedge gel at 180 v overnight at room temp-
erature. On completion, the alleles were revealed by staining
with 0.5ytg ml ethidium bromide and transferring the gel to a
U.V. transilluminator. Scoring of LOH was based on the
intensity of the two alleles in the lymphocyte versus the
tumour lanes.
Results
We characterised the tumours both by histology and grade,
then recorded the tumour-stroma proportion as percentage
tumour as set out in Table I. DNA from 28 tumour-normal
pairs was analysed on Southern blots and polyacrylamide
gels (where appropriate), using the nine RFLP DNA probes
and the two oligonucleotide primer pairs.
LOHand amplification at 1q13
At 1q13 there was a low level of LOH: 3/16 with FGF3,
1/14 with FOLRI (Figure 1). There were no cases of inter-
stitial deletion. Amplification of this region was also seen in a
small number of tumours: 4/28 with FGF3, 4/25 with FOLRI
(Table II). In those cases of amplification where there was
heterozygosity, there was no LOH of the unamplified allele
and no genomic rearrangements were evident with any of the
1q13 probes studied. The degree of amplification of 1q13
was 1-2 extra copies as measured by densitometry.
LOH telomeric to 11q13
LOH became more marked as probes more telomeric to
11ql3 were used. At 11ql4-21 (TYR), only 3/16 cases had
LOH, but 6/11 showed LOH at STMY1 (11q22), 5/17 at
DI1S144 (1lq22.3-23.3), 7/15 at DIIS29 (1lq23.3), 7/16 at
CD3D (1lq23.3) and 8/12 at DIIS147 (llq23.3-qter). The
results from the thirteen tumours that showed LOH on llq
were compatible with the conclusion that a putative tumour
suppressor gene is situated telomeric to CD3D. Tumours 10,
25 and 47 provided the strongest evidence that llq23.3-qter
Table I Histological subtype, grade, percentage tumour and clinical stage from the samples studied
Tumour
number Histological classification Grade Percentage tumoura Clinical stageb
7 Adenocarcinoma, undifferentiated lineage 3 80 NA
9 Adenocarcinoma, undifferentiated lineage 3 50 NA
10 Serous papillary adenocarcinoma 3 50-60 NA
11 Serous papillary adenocarcinoma 3 75 NA
13 Mucinous cystadenocarcinoma 1 45 NA
17 Papillary adenocarcinoma 3 75 NA
20 Serous papillary cystadenocarcinoma 2 75 NA
24 Adenocarcinoma, undifferentiated lineage 3 50 III
25 Serous papillary cystadenocarcinoma 3 80-90 III
27 Papillary carcinoma 3 45-50 III
28 Serous papillary cystadenocarcinoma 2-3 75 NA
29 Serous papillary cystadenocarcinoma 2-3 80 III
30 Mucinous adenocarcinoma 1 50 III
31 Endometrioid adenocarcinoma 2 50 III
32 Serous papillary adenocarcinoma 2-3 75 III
37 Serous papillary adenocarcinoma 3 90 II
40 Endometrioid adenocarcinoma 3 60 III
41 Serous adenocarcinoma 3 80 III
42 Endometrioid adenocarcinoma 2 80 NA
47 Adenocarcinoma, undifferentiated lineage 2 80 IV
48 Serous papillary adenocarcinoma 3 80 II
50 Mixed Mullerian tumour 3 95 III
51 Mucinous adenocarcinoma 1 75 III
53 Serous papillary adenocarcinoma 2 60 IV
61 Serous papillary adenocarcinoma 2 25-30 III
64 Adenocarcinoma, undifferentiated lineage 3 90 II
67 Serous papillary adenocarcinoma 3 80 III
73 Endometrioid adenocarcinoma 2 85 II
aThe percentage tumour in the sample used to extract the DNA was estimated from frozen sections as described in Materials and methods. bStaging based on FIGO classification. NA: Not available.270 W.D. FOULKES et al.
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Figure 1 Shown here are the results of Southern blot hybridisation and PCR amplification using the DNA markers/olig-
onucleotide primers indicated. Ordinates: Probes used, with their chromosomal location. Abcissae: Tumours studied by number.
Symbols used as: 0, Constitutional heterozygosity with LOH; 0, Constitutional heterozygosity with no LOH; 0, Homozygous;
Blank space, Not tested/ not determined. For full details of the probes and primers used at each locus, see Materials and methods.
The histopathological classification and grading of the tumours is shown in Table I.
Table II Amplification of 1 1q13 in ovarian carcinoma
D11SJ46 FGF3 FOLRI
11q12-13.2 11ql3.3-13.5 llql3.3-13.5
7 +a+ +
10 - + +
24 - + +
73 - + +
Ordinates: Tumour numbers, abcissae: probes used with
chromosomal location. aIn all tumours marked +, the amplification
comprised only one extra copy of that allele and did not extend to
markers telomeric to 1q13, as shown in Figure 2. Absence of
amplifcation is marked by a dash (-).
is the most likely site of such a gene. Representative auto-
radiographs of these results are shown in Figure 2, next to a
karyogram of llq.
Dinucleotide repeat PCR-LOH
Examples of the results obtained with the PCR primers
L7.1/2 (DIIS29) and Mfd69 (CD3D) are shown in Figure 3.
11.2-
11.1-
7
23-
-24
25-
10
I
DllS146
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C
FOLR1
Sample 47 showed LOH with DIISJ47, an RFLP marker, at
1 q23.3-qter (Figure 2), but retention at DIIS29 and CD3D,
(both at llq23.3) (Figure 3). The relative intensity of the
alleles in these cases remained constant with both shorter (15)
and longer (40) cycles, thus demonstrating that the absence
of LOH was not due to amplification of 'contaminating'
stroma, but due to retention of heterozygosity in the tumour
specimen (data not shown).
LOH andamplification ofHRAS
In order to ascertain whether or not LOH and amplification
on lq was due to loss and/or duplication of the whole
chromosome, we used a probe derived from the HRAS gene,
at lilpl5.5. Our results using this probe, pH06T1, (LOH
2/13, amplification 2/26) confirmed that 1 lq events were
specific to that arm. The two tumours with amplification at
HRAS retained heterozygosity, and again there were 1-2
extra copies of the amplified allele. The conclusion that
amplification and not loss had taken place was based on
repeat hybridisation with probes from other chromosomes
(data not shown). Chromosomal duplication was not present,
11
D1 1S146
FGF3
FOLR1
25
I
A
B1
FGF3
B2
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47
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Figure 2 A selection of tumours showing either LOH or amplification is shown. Key: E Constitutional homozygosity, no
amplification; Constitutional homozygosity, with amplification; [I] No LOH, no amplification; LOH, no
amplification; I No amplification, no LOH. On the left is a partial karyogram of chromosome 11 with the approximate
positions of the probes used. The columns (tumour number indicated above) set out the interpretation of the autoradiographs
pictured relative to the karyogram. The autoradiographs are labelled individually if the current chromosomal assignments of the
probes overlap. In each pair of bands, the left hand band is normal tissue and the right, tumour. C represents a constant band
(FOLRI, samples 7 and 10) and the amplified allele is marked with an asterisk. The loading for each pair is within 10% except
where marked by an arrow. In this case (l1, FGF3), there is -I100% more DNA loaded in the tumour lane than the corresponding
normal lane. As the smaller allele is faint, the alleles have been designated A and B and their positions are shown next to the
autoradiograph. The full names of the probes and their chromosomal position is given in the text.
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Figure 3 Dinucleotide repeat primers pairs L7.1/2 (DIIS29) and Mfd69 (CD3D) were used to amplify genomic DNA from
normal-tumour pairs. In each case, lymphocyte DNA is on the left, tumour on the right. The alleles were visualised as described in
the text. LOH is seen with both markers in tumour 37 and heterozygosity is retained in 32 and 47. With tumour 48, there is LOH
at DIIS29, but this sample is homozygous at CD3D.
because in all cases, those tumours with LOH or
amplification on lip did not show the same phenomena on
1lq.
LOH andgrade
LOH on llq was more common in advanced tumours, as
there was an increasing percentage of LOH when comparing
histopathological grades 1, 2 and 3 (Table III), but this trend
was not significant. The lack of significance may be due to
the small number of tumours studied, with a bias towards
advanced tumours. There was also no significant correlation
between histological type and LOH on llq.
Discussion
Chromosome 11q has been studied in many tumours and in
particular there has been extensive investigation of 11 q13 in a
large number of solid and haematological tumours (Lammie
& Peters, 1991). The region appears to contain a number of
cancer-related genes, and on average, between 5 and 50% of
tumours of various types show modest amplification of some
or all of this large band. Amplification at 11q13 in our study
was at a frequency similar to the 1/16 cases reported in EOC
by Sasano et al. (1990) which is at the lower end of the range
previously reported for other tumours. The copy number is
slightly lower than that reported in breast cancer, which is
usually 3-10 fold (Lammie & Peters, 1991). It is likely that
the gene(s) around the bc1l breakpoint (Motokura et al.,
1991; Rosenberg et al., 1991; Schuuring et al., 1992) is driv-
ing amplification seen in EOC.
FOLRI overexpression in ovarian carcinoma is thought to
be the result of increased transcription, but the mechanism
by which this occurs has not been elucidated (Campbell et
al., 1991). However, our results have demonstrated that
neither amplification nor LOH can explain this elevation and
therefore the mechanism is probably not genetic in origin but
may relate to local factors such as low levels of folate and
subsequent upregulation of expression of the FOLRI gene
(Campbell et al., 1991).
Table III LOH in ovarian cancer on 1lq by histopathological
grade
Gradea LOHb (%)
1 0/3 (0)
2 4/7 (57)
3 10/15 (67)
aTumour grade was determined as discussed in Materials and
methods. bLoss of heterozygosity shown as cases with LOH over the
total number of informative cases. Three tumours were graded 2-3;
none of these tumours showed LOH. The numbers are not large
enough for statistical analysis.
In contrast to the low level of LOH at 11q13, which could
be due to either mitotic recombination just proximal to this
region, or to loss of the whole arm (with or without redup-
lication) we have demonstrated 67% LOH at llq23.3-qter.
The minimum region of LOH is telomeric to the Mfd69
marker at CD3D (1 Iq23.3). This suggests a recombination
event is occurring just centromeric of DIIS147 in Tumours
10, 25 and 47 (Figure 4). A number of cytogenetic reports in
ovarian tumours have noted the consistent, but infrequent
finding of translocations and deletions involving l1q23-q25
(Jenkyn & McCartney, 1987; Pejovic et al., 1989; Bello &
Ray, 1990; Pejovic et al., 1992). Interestingly, a translocation
t(I;ll)(q25;q23) was seen as the only karyotypic abnormality
in a mucinous cystadenoma (Pejovic et al., 1990), suggesting
that such translocations may be significant early events in the
pathogenesis of malignant ovarian neoplasia. How these
reports in ovarian tumours relate to the much more com-
monly seen (and better characterised) 11q23 translocations in
haematological disorders is unknown at present, but interest-
ingly, data from studies in acute leukaemia and lymphoma
(Zieman-van der Poel et al., 1991) suggest that one of the
breakpoint regions present on chromosome 11 in a number
of different haematological malignancies is approximately
200 kb telomeric to CD3D. The region around CD3D may be
important for a number of different malignancies including
EOC. Figure 4 demonstrates the LOH seen in three tumours
at DIIS144, DIIS29, CD3D and D11S147. The positions of
these markers shown in the figure are based on the publica-
tions of Foroud et al. (1991); Zieman-van der Poel et al.
(1991) and Heutink et al. (1992).
It is noteworthy that two fragile sites (FRAlIB, rare and
folic acid sensitive, and FRAlIG, common and aphidicolin
Approx. position of breakpoint in leukaemias
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Figure 4 The most likely order of the loci DIIS144, DIIS29,
CD3D and DIIS147 used in this study is shown. The distance
between markers, in centimorgans (cM) is based on sex-averaged
recombination fractions, and is not to scale. Theta is the female
recombination rates between markers. The figure is based on the
genetic mapping data of Foroud et al. (1991) and Heutink et al.
(1992) and the physical data of Zieman-van der Poel et al. (1991).
Loss of heterozygosity in ovarian tumour pairs 10, 25 and 47 is
shown below. 0 LOH, 0 No LOH; ND Not Done/Not Deter-
mined.
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sensitive) are present at 1 1q23.3. However, there are no
published reports of possible involvement of these two sites
in the evolution of any human cancer, nor are they thought
to be coincident upon known breakpoints. Support for the
fragile site hypothesis of cancer appears generally to be wan-
ing (Hecht, 1988) and although it is possible that random
chromosomal breakages occur more frequently at fragile sites
in the later stages of neoplasia, there are no data to support
a causal role.
Our molecular studies suggest that functional deletions of
genes on llq23.3-qter may be more common in EOC that is
suggested by the cytogenetic data. Very recently Heutink et
al. (1992) reported linkage of hereditary paragangliomas in a
large Dutch pedigree to DJJS147, a probe used in the present
study which is an anonymous DNA marker mapping to
1lq23.3-qter. This finding supports the notion that there is a
gene implicated in tumourigenesis adjacent to or telomeric of
1lq23.3 and thus this region appears to be important in a
number of different tumours types. An expanded LOH study
using recently described polymorphic markers from 1lq23.3-
1 lqter (Tanigami et al., 1992) should lead to a finer mapping
of this deletion in ovarian cancer.
The data presented here suggest that LOH and
amplification on llq are quite distinct events that involve
separate regions of the chromosome. We have shown by
LOH studies that the minimal region of LOH on
chromosome llq in EOC is llq23.3-qter. The high level of
LOH at 1lq23.3-qter in EOC reported here brings the
number of chromosomal loci significantly involved (>50%
LOH) in these tumours to eight: 3p (Ehlen & Dubeau, 1990);
6p (Sato et al., 1991); 6q (Ehlen & Dubeau, 1990; Lee et al.,
1990); 1Ip (Lee et al., 1989; Lee et al., 1990); 1lq (this
study); 17p (Lee et al., 1990; Eccles et al., 1990; Tsao et al.,
1991); 17q (Russell et al., 1990; Eccles et al., 1990; Foulkes et
al., 1991) and 18q (Chenevix-Trench et al., 1992). In our
experience, the late stage tumours are likely to show con-
comitant loss of most of these regions.
We would like to thank Dr G. Peters for critically reading the
manuscript, and also all the clinicians and other hospital staff who
have provided us with the specimens used in this study. The probes
were kindly provided by HGMP Harrow, UK, Dr T. Tedder, Dr C.
Dickson and Dr G. Peters.
References
ANDERSON, M.C. (1991). In Tumours of the ovary II: epithelial
(serosal) tumours. Systemic Pathology, Third edition, Vol 6, Sym-
mers, W.St.C. (ed.). pp. 303-344. Churchill Livingstone: Edin-
burgh.
BELLO, M.J. & REY, J.A. (1990). Chromosome aberrations in metas-
tatic ovarian cancer: relationship with abnormalities in primary
tumors. Int. J. Cancer, 45, 50-54.
CAMPBELL, I.G., JONES, T.A., FOULKES, W.D. & TROWSDALE, J.
(1991). Folate-binding protein is a marker for ovarian cancer.
Cancer Res., 51, 5329-5338.
CHENEVIX-TRENCH, G., LEARY, J., KERR, J., MICHEL, J., KEF-
FORD, R., HURST, T. PARSONS, P.G., FRIENDLANDER, M. &
KHOO, S.K. (1992). Frequent loss of heterozygosity on chromo-
some 18 in ovarian adenocarcinoma which does not always in-
clude the DCC locus. Oncogene, 7, 1059-1065.
CONEY, L.R., TOMASSETTI, A., CARAYANOPOULOS, L., FRASCA,
V., KAMEN, B.A., COLNAGHI, M.I. & ZURAWSKI, V.R. (1991).
Cloning of a tumor-associated antigen: MOvi8 and MOvi9
antibodies recognise a folate binding protein. Cancer Res., 51,
6125-6132.
ECCLES, D.M., CRANSTON, G., STEEL, C.M., NAKAMURA, Y. &
LEONARD, R.C.F. (1990). Allele loss on chromosome 17 in a
human epithelial cancer. Oncogene, 5, 1599-1601.
EHLEN, T. & DUBEAU, L. (1990). Loss of heterozygosity on chromo-
somal segments 3p, 6q and lIp in human ovarian cancer. Onco-
gene, 5, 219-223.
ELWOOD, P.C. (1989). Molecular cloning and characterisation of the
human folate-binding protein cDNA from placenta and malig-
nant tissue culture (KB) cells. J. Biol. Chem., 264, 14893-14901.
FEINBERG, A.P. & VOGELSTEIN, B. (1983). A technique for radio-
labelling DNA restriction endonuclease fragments to high specific
activity. Analyt. Biochem., 132, 6-13.
FOROUD, T., WEI, S., ZIV, Y., SOBEL, E., LANGE, E., CHAO, A.,
GORADIA, T., HUO, Y., TOLUN, A., CHESSA, L., CHARMLEY, P.,
SANAL, O., SALMAN, N., JULIER, C., CONCANNON, P., McCON-
VILLE, C., TAYLOR, A.M.R., SHILOH, Y., LANGE, K. & GATTI,
R.A. (1991). Localization of an Ataxia-Telangiectasia locus to a
3-cM interval on chromosome 1 1q23: linkage analysis of 111
families by an international consortium. Am. J. Hum. Genet., 49,
1263-1279.
FOULKES, W., BLACK, D.M., SOLOMON, E. & TROWSDALE, J.
(1991). Allele loss on chromosome 17q in sporadic ovarian
cancer. Lancet, 338, 444-445.
FRIEDMAN, E., SAKAGUCHI, K., BALE, A.E., FALCHETTI, A.,
STREETEN, E., ZIMMERMAN, M.B., WEINSTEIN, L.S., MCBRIDE,
W.O., NAKAMURA, Y., BRANDI, M.-L., NORTON, J.A., AUR-
BACH, G.D., SPIEGEL, A.M. & MARX, S.J. (1989). Clonality of
parathyroid tumors in familial multiple endocrine neoplasia type
1. N. Engl. J. Med., 321, 213-218.
FUJIMORI, M., WELLS, S.A. & NAKAMURA, Y. (1992). Fine scale
mapping of the gene responsible for multiple endocrine neoplasia
type 1 (MENI). Am. J. Hum Genet., 50, 399-403.
FUTREAL, P., SODERKVIST, P., MARKS, J.R., IGLEHART, J.D.,
COCHRAN, C., BARRETT, J.C. & WISEMAN, R.W. (1992). Detec-
tion of frequent allelic loss on proximal chromosome 17 in
sporadic breast carcinoma using microsatellite length polymor-
phisms. Cancer Res., 52, 2624-2627.
GOELZ, S.E., HAMILTON, S.R. & VOGELSTEIN, B. (1985).
Purification of DNA from formaldehyde fixed and paraffin
embedded tissue. Biochem. Biophys. Res. Comm., 130, 118-126.
HECHT, F. (1988). The fragile site hypothesis of cancer. Cancer
Genet. Cytogenet., 31, 119-121.
HEUTINK, P., VAN DER MAY, A.G.L., SANDKUIJIL, L.A., VAN GILS,
A.P.G., BARDOEL, A., BREEDVELD, G.J., VAN VLIET, M., VAN
OMMEN, G.-J.B., CORNELISSE, C.J., OOSTRA, B.A., WEBER, J.L. &
DEVILEE, P. (1992). A gene subject to imprinting and responsible
for hereditary paraganglionomas maps to chromosome llq23-
qter. Hum. Mol. Genet., 1, 7-10.
JENKYN, D.J. & McCARTNEY, A.J. (1987). A chromosome study of
three ovarian tumors. Cancer Genet. Cytogenet., 26, 327-337.
LAMMIE, G.A. & PETERS, G. (1991). Chromosome 1ql3 abnor-
malities in human cancer. Cancer Cells, 3, 414-420.
LARSSON, C., SKOGSEID, B., OBERG, K., NAKAMURA, Y. & NORD-
ENSKJOLD, N. (1988). Multiple endocrine neoplasia type 1 gene
maps to chromosome 11 and is lost in insulinoma. Nature, 332,
85-87.
LEE, J.H., KAVANAGH, J.J., WHARTON, J.T., WILDRICK, D.M. &
BLICK, M. (1989). Allele loss at the c-Ha-rasl locus in human
ovarian cancer. Cancer Res., 49, 1220-1222.
LEE, J.H., KAVANAGH, J.J., WILDRICK, D.M., WHARTON, J.T. &
BLICK, M. (1990). Frequent loss of heterozygosity on chromo-
somes 6q, 11 and 17 in human ovarian carcinomas. Cancer Res.,
50, 2724-2728.
LI, S.-B., SCHWARTZ, P.E., LEE, W.H. & YANG-FENG, T.L. (1991).
Allele loss at the retinoblastoma locus in human ovarian cancer.
J. Natl Cancer Inst., 83, 637-640.
MIOTTI, S., CANEVARI, S., MENARD, S., MEZZANZANICA, D., POR-
RO, G., PUPA, S.M., REGANZZONI, M., TAGLIABUE, E. & COL-
NAGHI, M.I. (1987). Characterisation of human ovarian carci-
noma-associated antigens defined by novel monoclonal antibodies
with tumor-restricted specificity. Int. J. Cancer, 39, 297-303.
MOTOKURA, T., BLOOM, T., KIM, H.G., JUPPNER, H., RUDERMAN,
J.V., KRONENBERG, H.M. & ARNOLD, A. (1991). A novel cyclin
encoded by a bcll-linked candidate oncogene. Nature, 350, 512-
515.
MOLLENBACH, R., LAGODA, P.J.L. & WELTER, C. (1989). An
efficient salt-chloroform extraction of DNA from blood and tis-
sues. Trends Genet., 5,'391.
PEJOVIC, T., HEIM, S., MANDHAL, N., ELMFORS, B., FLODERUS,
U.-M., FURGYIK, S., HELM, G., WILLEN, H. & MITELMAN, F.
(1989). Consistent occurrence of a l9p + marker chromosome
and loss of lip material in ovarian seropapillary cystadenocar-
cinomas. Genes Chromosom. Cancer, 1, 167-171.CHROMOSOME 11q IN OVARIAN CANCER 273
PEJOVIC, T., HEM, S., MANDHAL, N., ELMFORS, B., FLODERUS,
U.-M., FURGYIK, S., HELM, G., WILLEN, H. & MITELMAN, F.
(1990). Trisomy 12 is a consistent chromosomal aberration in
benign ovarian tumors. Genes Chromosom. Cancer, 2, 48-52.
PEJOVIC, T., HEIM, S., MANDHAL, N., BALDETORP, B., ELMFORS,
B., FLODERUS, U.-M., FURGYIK, S., HELM, G., HIMMELMANN,
A., WILLEN, H. & MITELMAN, F. (1992). Chromosome aberration
in 35 primary ovarian carcinomas. Genes Chromosom. Cancer, 4,
58-68.
RAGOUSSIS, J., SENGER, G., TROWSDALE, J. & CAMPBELL, I.
(1992). Genomic organisation of the human folate receptor genes
on chromosome llql3. Genomics, 14, 423-430.
RATNAM, M., MARQUARDT, H., DUHRING, J.L. & FREISHEIM, J.H.
(1989). Homologous membrane folate binding proteins in human
placenta: cloning and sequence of a cDNA. Biochemistry, 28,
8249-8254.
ROSENBERG, C.L., KIM, H.G., SHOWS, T.B., KRONENBERG, H.M. &
ARNOLD, A. (1991). Rearrangement and overexpression of DlIS-
287E, a candidate oncogene on chromosome 1 1q13 in benign
parathyroid tumours. Oncogene, 6, 449-453.
RUSSELL, P. (1987). Common epithelial tumours of the ovary In:
Obstetrical and Gynaecological Pathology, Third edition, Vol. 1,
Fox, H. (ed.). pp. 556-622. Churchill Livingstone: Edinburgh.
RUSSELL, S.E.H., HICKEY, G.I., LOWRY, W.S., WHITE, P. & ATKIN-
SON, R.J. (1990). Allele loss from chromosome 17 in ovarian
cancer. Oncogene, 5, 1581-1583.
SASANO, H., GARRETT, C.T., WILKINSON, D.S., SILVERBERG, S.,
COMERFORD, J. & HYDE, J. (1990). Protooncogene amplification
and tumor ploidy in human ovarian neoplasms. Hum. Pathol., 21,
382-391.
SATO, T., SAITO, H., MORITA, R., KOI, S., LEE, J.H. & NAKAMURA,
Y. (1991). Allelotype of human ovarian cancer. Cancer Res., 51,
5118-5122.
SCHUURING, E., VERHOEVEN, E., MOOI, W.J. & MICHALIDES,
R.J.A.M. (1992). Identification and cloning of two overexpressed
genes, U21B31/PRAD1 and EMS1, within the amplified chromo-
some 11q13 region in human carcinomas. Oncogene, 7, 355-361.
SEROV, S.F., SCULLY, R.E. & SOBRIN, L.H. (1973). Histological typ-
ing of ovarian tumours. In: International Histological
Classification of Tumours, Number 9. pp. 17-54. World Health
Organization: Geneva.
SRIVATSAN, E.S., MISRA, B.C., VENUGOPALAN, M. & WILCZYNSKI,
S.P. (199la). Loss ofheterozygosity for alleles on chromosome 11
in cervical carcinoma. Am. J. Hum. Genet., 49, 868-77.
SRIVATSAN, E.S., MURALI, V. & SEEGER, R.C. (1991b). Loss of
heterozygosity for alleles on chromosome Ilq and 14q in neuro-
blastoma. Prog. Clin. Biol. Res., 366, 91-98.
TANIGAMI, A., TOKINO, T., TAKIGUCHI, S., MORI, M., GLASER, T.,
PARK, J.W., JONES, C. & NAKAMURA, Y. (1992). Mapping of 262
DNA markers into 24 intervals on human chromosome 11. Am.
J. Hum. Genet., 50, 56-64.
THAKKER, R.V., BOULOUX, P., WOODING, C., CHOTAI, K., BROAD,
P.M., SPURR, N.K., BESSER, G.M. & O'RIORDAN, J.L.H. (1989).
Association of parathyroid tumors in multiple endocrine neo-
plasia type 1 with loss of alleles on chromosome 11. N. Engl. J.
Med., 321, 218-224.
TSAO, S.W., MOK, C.-H., OIKE, K., MUTO, M., GOODMAN, H.M.,
SHEETS, E.E., BERKOWITZ, R.S., KNAPP, R.C. & LAU, C.C.
(1991). Involvement of p53 gene in the allele deletion of chromo-
some 17p in human ovarian tumours. Anticancer Res., 11, 1975-
1982.
TSUJIMOTO, Y., JAFFE, E., COSMAN, J., GORMAN, J., NOWELL, P.C.
& CROCE, C.M. (1985). Clustering ofbreakpoints on chromosome
11 in human B-cell neoplasms with the t(l 1;14) chromosome
translocation. Nature, 315, 340-343.
VIEL, A., DE PASCALE, L., TOFFOLI, G., TUMIOTTO, L., MIOTTO, E.
& BIOCCHI, M. (1991). Frequent occurrence of H-rasl alleleic
deletion in human ovarian adenocarcinomas. Tumori, 77, 16-20.
WARNICH, L., GROENEWALD, I., THEART, L. & RETIEF, A.E.
(1992). Highly informative dinucleotide repeat polymorphism at
the DlIS29 locus on chromosome 11q23. Hum. Genet., 89,
357-359.
WEBER, J.L., KWITEK, A.E. & MAY, P.E. (1990). Dinucleotide repeat
polymorphisms at the D1IS419 and CD3D loci. Nucleic. Acids
Res., 18, 4036.
ZIEMAN-vAN DER POEL, S., MCCABE, N.R., GILL, H.J., ESPINOSA, R.,
PATEL, Y., HARDEN, A., RUBINELLI, P., SMITH, S.D., LEBEAU,
M.M., ROWLEY, J.D. & DIAZ, M.O. (1991). Identification of a
gene, MLL, that spans the breakpoint in 1 1q23 translocations
associated with human leukemias. Proc. Natl Acad. Sci. (USA),
88, 10735-10739.